Weight loss peptides and medications
Losing weight is less about willpower than about biology: hunger hormones, blood sugar swings, and metabolism all push back. These articles look at the weight loss peptides and medications researchers study — how they work, what results have been measured, and what a realistic plan looks like alongside food and movement.
Nothing here is a shortcut or a guarantee. Medication is one tool, prescribed only when a licensed provider decides it fits your situation. Every article below is specific about what was measured and in whom.
81 articles on this topic
-
Tirzepatide vs Ozempic: What You're Comparing
Ozempic is a brand of semaglutide, approved for type 2 diabetes. Tirzepatide is a different molecule with its own brands — so the comparison most people want is between two drugs, not a drug and a label.
-
GLP-1 Patches: Do They Work?
GLP-1 patches sold online are usually supplement stickers, not semaglutide or tirzepatide. Ordinary patches cannot move these large peptide drugs across intact skin in a predictable dose.
-
Semaglutide L-Carnitine: What the Additive Means
Some compounders add L-carnitine for its role in fat metabolism. The rationale is real biology, but no human trial shows that mixing it with semaglutide improves weight-loss outcomes.
-
Sermorelin for Weight Loss: What Studies Show
Sermorelin is not a weight-loss drug. It changes growth-hormone signaling, but small older-adult studies found hormone effects without reliable scale-weight loss.
-
Tirzepatide for Weight Loss: What to Know
Tirzepatide for weight loss is a once-weekly prescription treatment studied alongside diet and physical activity. Here is who SURMOUNT-1 enrolled, what it found, and what long-term care involves.
-
Semaglutide for Weight Loss: What It Involves
Semaglutide for weight loss is a prescription treatment used alongside lower-calorie eating and physical activity. Its effects build over months, and individual results depend on continued treatment, tolerability, and clinical fit.
-
Foods to Avoid on Tirzepatide: A Practical Guide
There is no universal ban list. Smaller portions and fewer fried, high-fat, fizzy, or alcohol-heavy choices may make nausea, reflux, bloating, and fullness easier to manage.
-
Semaglutide and Pancreatitis: What Studies Show
Randomized trials have not shown more acute pancreatitis with semaglutide than with placebo, but the event is rare and remains a prescribing-label warning. Persistent, severe abdominal pain needs prompt medical attention.
-
Tesamorelin for Belly Fat: What the Studies Show
Tesamorelin has reduced visceral abdominal fat in randomized trials, most convincingly in adults with HIV-associated lipodystrophy. That evidence does not make it a general weight-loss drug or a reliable way to shrink the fat just under the skin.
-
Tirzepatide for PCOS: What the Evidence Shows
Early studies connect tirzepatide with weight and metabolic changes in people with PCOS, but the direct evidence is still small. Pregnancy plans and the reason for prescribing matter as much as the diagnosis.
-
Tirzepatide Plateau: Why Weight Loss Slows
A tirzepatide plateau is usually the point where a smaller body and stronger biological pressure to maintain weight balance the medication's effects. A brief stall is not the same thing, and a prescriber should review the pattern before changing treatment.
-
Semaglutide and Pregnancy: What the Evidence Says
Semaglutide is not recommended for routine weight management during pregnancy. The label calls for a two-month gap before planned conception, while early human exposure data remain limited rather than conclusive.
-
Tirzepatide Benefits: What the Trials Show
Tirzepatide benefits are best established for weight reduction and blood-sugar control, with a branded indication for moderate-to-severe sleep apnea in adults with obesity. Heart failure, liver, blood-pressure and lipid findings are promising but narrower.
-
Liraglutide vs Semaglutide: A Clear Comparison
Both are GLP-1 medicines, but liraglutide is usually injected daily and semaglutide weekly. Head-to-head trials show why the treatment goal and dose matter as much as the molecule.
-
Tirzepatide Long-Term Side Effects: 3-Year Data
Three-year weight-management data and four-year cardiovascular data have not revealed a new late safety signal. They also do not tell us what decades of exposure will look like.
-
What Happens When You Stop Taking Tirzepatide?
Appetite suppression fades as tirzepatide clears, and weight regain is common but neither immediate nor inevitable. SURMOUNT-4 shows the difference between stopping and continuing over one year.
-
Peptides for Insulin Resistance: Evidence
The evidence runs from large clinical trials for semaglutide and tirzepatide to animal and observational research for MOTS-c. Those are not interchangeable levels of certainty.
-
Does Semaglutide Cause Muscle Loss?
Semaglutide-related weight loss can include a drop in lean mass, but DXA lean mass is not the same as skeletal muscle. STEP 1 found fat fell faster than lean tissue, improving lean mass as a share of body weight.
-
GLP-1 Drops: What the Absorption Evidence Shows
GLP-1 drops promise a needle-free shortcut, but the delivery system is the whole question. No published human clinical evidence yet shows that sublingual semaglutide drops achieve meaningful absorption or weight-loss efficacy.
-
Does Semaglutide Make You Tired? What Trials Show
Yes, fatigue can happen, though it was reported by a minority of people in STEP trials. The timing and accompanying symptoms help distinguish low intake or dehydration from hypoglycemia or another cause.
Page 3 of 5 · 81 articles